EHP-102

EHP-102
Clinical data
Other namesEHP102; VCE-003.2; VCE003.2
Routes of
administration		Oral
Drug classCannabinoid CB2 receptor agonist; PPARγ agonist
Identifiers
  • 3-[(2E)-3,7-dimethylocta-2,6-dienyl]-5-(ethylamino)-4-hydroxy-6-pentylcyclohexa-3,5-diene-1,2-dione
CAS Number
PubChem CID
DrugBank
UNII
Chemical and physical data
FormulaC23H35NO3
Molar mass373.537 g·mol−1
3D model (JSmol)
  • CCCCCC1=C(C(=C(C(=O)C1=O)C/C=C(\C)/CCC=C(C)C)O)NCC
  • InChI=1S/C23H35NO3/c1-6-8-9-13-18-20(24-7-2)21(25)19(23(27)22(18)26)15-14-17(5)12-10-11-16(3)4/h11,14,24-25H,6-10,12-13,15H2,1-5H3/b17-14+
  • Key:MRCQPMQBCKEOCU-SAPNQHFASA-N

EHP-102, also known as VCE-003.2, is a cannabinoid CB2 receptor agonist and PPARγ agonist which is under development for the treatment of Parkinson's disease and Huntington's disease. It is taken orally. The drug is a derivative of cannabigerol (CBG). It is under development by Emerald Health Sciences. As of February 2024, it is in the preclinical research stage of development for both Parkinson's disease and Huntington's disease, but no recent development has been reported for Huntington's disease.

See also

References

  1. 1 2 3 4 5 "EHP 102". AdisInsight. 28 February 2024. Retrieved 2 June 2026.
  2. 1 2 3 "Delving into the Latest Updates on EHP-102 with Synapse". Synapse. 24 May 2025. Retrieved 2 June 2026.
  3. 1 2 3 Shaffer C (1 March 2020). "Medical Cannabis Pioneers Stake Their Claims: Across the medical cannabis frontier, natural cannabinoids, synthetic analogues, rationally designed ligands, and prodrugs are being developed". Genetic Engineering & Biotechnology News. 40 (3): 52–55. doi:10.1089/gen.40.03.14. ISSN 1935-472X.
  4. 1 2 Díaz-Alonso J, Paraíso-Luna J, Navarrete C, Del Río C, Cantarero I, Palomares B, et al. (July 2016). "VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington's disease". Scientific Reports. 6 29789. doi:10.1038/srep29789. PMC 4949444. PMID 27430371.